Clinical Trials
148 trialsNCT00885066 2026-04-23
Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer
Centre Antoine Lacassagne
Phase 1 Completed
NCT03403049 2026-04-13
Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer
Montefiore Medical Center
Phase 1 Completed
NCT05064085 2026-04-06
Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02669173 2026-02-23
Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma
Case Comprehensive Cancer Center
Phase 1 Completed
NCT04664829 2025-09-23
The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC
National Cancer Centre, Singapore
Phase 1 Completed
NCT04047862 2025-08-22
Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors
BeiGene
Phase 1 Completed
NCT05625412 2025-06-13
A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed
NCT04942626 2025-02-21
ACO/ARO/AIO-21
Goethe University
Phase 1 Completed
NCT03916510 2025-02-06
CEDAR
University of Oxford
Phase 1 Completed
NCT02794571 2024-12-05
Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors
Genentech, Inc.
Phase 1 Completed
NCT02892123 2024-11-27
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
Jazz Pharmaceuticals
Phase 1 Completed
NCT02009449 2024-11-15
IVY
Eli Lilly and Company
Phase 1 Completed
NCT04861987 2024-10-10
A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors
Processa Pharmaceuticals
Phase 1 Completed
NCT00483366 2024-09-23
Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors
University of Nebraska
Phase 1 Completed
NCT03641547 2024-07-18
CHARIOT
University of Oxford
Phase 1 Completed
NCT04357587 2024-05-29
Safety and Feasibility of PD-1 Blockade in the Treatment of dMMR or MSI-H Rectal Cancer
Case Comprehensive Cancer Center
Phase 1 Completed
NCT00486356 2024-01-03
Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer
University of Nebraska
Phase 1 Completed
NCT02754011 2023-12-07
GEP14-LEECAP
UNICANCER
Phase 1 Completed
NCT01300962 2023-12-04
Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 1 Completed
NCT03958721 2023-11-27
Capecitabine and Radiotherapy in the Adjuvant Treatment of Resistant Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 1 Completed
NCT02483247 2023-11-14
A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT00084734 2023-08-04
Docetaxel, Capecitabine, and Cisplatin in Treating Patients With Advanced Solid Tumors
Roswell Park Cancer Institute
Phase 1 Completed
NCT00107250 2023-08-04
AZD2171 + Chemotherapy in Advanced NSCLC, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8/9/07)
Canadian Cancer Trials Group
Phase 1 Completed
NCT05052437 2023-01-10
PK and Drug Interaction Study of Utidelone Plus Capecitabine in Patients With Advanced Breast Cancer
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 1 Completed
NCT00807859 2022-11-08
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
Amgen
Phase 1 Completed
NCT03473639 2022-11-01
Breast49
University of Virginia
Phase 1 Completed
NCT00291486 2022-10-10
Capecitabine and 131I-huA33 in Patients With Metastatic Colorectal Cancer
Ludwig Institute for Cancer Research
Phase 1 Completed
NCT02394535 2022-09-02
Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01497392 2022-07-22
Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers
Roswell Park Cancer Institute
Phase 1 Completed
NCT03781362 2022-07-20
Study of CPI-100 in Patients With Advanced Tumors
Coordination Pharmaceuticals, Inc.
Phase 1 Completed
NCT01498458 2022-06-10
PazoX
GBG Forschungs GmbH
Phase 1 Completed
NCT03518242 2022-06-08
Molecular Profile of Breast Cancer in Ugandan Patients With Stage IIB-III Breast Cancer
Fred Hutchinson Cancer Center
Phase 1 Completed
NCT02451553 2022-06-07
Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer
University of Washington
Phase 1 Completed
NCT01918644 2022-06-01
Neoadjuvant SBRT With Concomitant Capecitabine in Resectable Pancreatic Cancer
University of Wisconsin, Madison
Phase 1 Completed
NCT02935309 2022-05-31
Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT01226732 2022-03-08
A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors
SCRI Development Innovations, LLC
Phase 1 Completed
NCT01802970 2021-10-08
Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients
Baylor Research Institute
Phase 1 Completed
NCT03152370 2021-10-04
PRAER 1
Adlai Nortye Biopharma Co., Ltd.
Phase 1 Completed
NCT02715531 2021-07-09
A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT02368860 2021-06-01
OXIRI
National Cancer Centre, Singapore
Phase 1 Completed
NCT01781403 2021-02-04
Preoperative CRT With Temozolomide Plus Capecitabine in Rectal Cancer
Asan Medical Center
Phase 1 Completed
NCT02650752 2021-01-26
Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT01471847 2020-12-09
A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab
Novartis
Phase 1 Completed
NCT02178644 2020-10-08
Pilot Trial of KD018 With Neo-Adjuvant Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Rectal Cancer
Yale University
Phase 1 Completed
NCT00710736 2020-10-06
A Study of ARRY-334543 and Capecitabine in Patients With Advanced Cancer
Array BioPharma
Phase 1 Completed
NCT03295084 2020-10-05
Safety, Tolerability and Pharmacokinetics of Oral Tablet of Irinotecan in Adult Patients With Solid Tumors
Herlev Hospital
Phase 1 Completed
NCT01634685 2020-08-20
A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal Adenocarcinoma
University of Texas Southwestern Medical Center
Phase 1 Completed
NCT00052273 2020-08-03
LY317615 Plus Capecitabine in Treating Patients With Advanced Solid Tumors
Jonsson Comprehensive Cancer Center
Phase 1 Completed
NCT04420871 2020-06-09
Pharmacokinetic and Safety Comparison of Two Capecitabine Tablets in Patients With Colorectal or Breast Cancer
The Affiliated Hospital of Qingdao University
Phase 1 Completed
NCT02025192 2020-06-04
A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer
Seagen Inc.
Phase 1 Completed